title: Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
abstract: OBJECTIVE
  To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS).
  
  
  METHODS
  Open-labeled drug administration to patients with AIDS and severe ulcerative disease due to acyclovir-resistant HSV-2 infection.
  
  
  METHODS
  Medical floors of acute care hospital.
  
  
  METHODS
  Four patients with AIDS who developed progressive ulcerative mucocutaneous lesions of the genitals, perineum, perianal region, or finger due to acyclovir-resistant, thymidine-kinase (TK)-negative strains of HSV-2.
  
  
  METHODS
  Foscarnet, 60 mg/kg body weight intravenously every 8 hours (with reduced dosage for renal impairment), for 12 to 50 days.
  
  
  RESULTS
  All patients receiving foscarnet had dramatic improvement in their clinical findings with marked clearing of mucocutaneous lesions and eradication of HSV from mucosal surfaces.
  
  
  CONCLUSIONS
  Foscarnet may be an effective treatment for severe mucocutaneous disease due to acyclovir-resistant, TK-negative strains of HSV-2.
authors.affiliation: University of California, San Francisco.
authors.forename: K S
authors.initials: KS
authors.lastname: Erlich
authors.forename: M A
authors.initials: MA
authors.lastname: Jacobson
authors.forename: J E
authors.initials: JE
authors.lastname: Koehler
authors.forename: S E
authors.initials: SE
authors.lastname: Follansbee
authors.forename: D P
authors.initials: DP
authors.lastname: Drennan
authors.forename: L
authors.initials: L
authors.lastname: Gooze
authors.forename: S
authors.initials: S
authors.lastname: Safrin
authors.forename: J
authors.initials: J
authors.lastname: Mills
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D017245:Foscarnet; D006561:Herpes Simplex / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D009943:Organophosphorus Compounds; D017245:Foscarnet; D010746:Phosphonoacetic Acid; D000212:Acyclovir